JP2012524112A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524112A5
JP2012524112A5 JP2012506296A JP2012506296A JP2012524112A5 JP 2012524112 A5 JP2012524112 A5 JP 2012524112A5 JP 2012506296 A JP2012506296 A JP 2012506296A JP 2012506296 A JP2012506296 A JP 2012506296A JP 2012524112 A5 JP2012524112 A5 JP 2012524112A5
Authority
JP
Japan
Prior art keywords
klk
pharmaceutical composition
seq
polypeptide
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012506296A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524112A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2010/000561 external-priority patent/WO2010121358A1/en
Publication of JP2012524112A publication Critical patent/JP2012524112A/ja
Publication of JP2012524112A5 publication Critical patent/JP2012524112A5/ja
Pending legal-status Critical Current

Links

JP2012506296A 2009-04-21 2010-04-21 統合失調症および双極性障害を治療するための組織カリクレイン Pending JP2012524112A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17118909P 2009-04-21 2009-04-21
US61/171,189 2009-04-21
PCT/CA2010/000561 WO2010121358A1 (en) 2009-04-21 2010-04-21 Tissue kallikrein for the treatment of schizophrenia and bipolar disorder

Publications (2)

Publication Number Publication Date
JP2012524112A JP2012524112A (ja) 2012-10-11
JP2012524112A5 true JP2012524112A5 (enExample) 2013-05-30

Family

ID=43010629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012506296A Pending JP2012524112A (ja) 2009-04-21 2010-04-21 統合失調症および双極性障害を治療するための組織カリクレイン

Country Status (6)

Country Link
US (1) US20120201804A1 (enExample)
EP (1) EP2421553A4 (enExample)
JP (1) JP2012524112A (enExample)
CN (1) CN102458453A (enExample)
CA (1) CA2759481A1 (enExample)
WO (1) WO2010121358A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ582930A (en) 2007-07-20 2012-11-30 Diamedica Inc Tissue kallikrein for the treatment of diseases associated with amyloid protein
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
US20130323222A1 (en) 2012-06-04 2013-12-05 Matthew Charles Human tissue kallikrein 1 glycosylation isoforms
US11174317B2 (en) 2015-06-04 2021-11-16 National Center Of Neurology And Psychiatry Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient
CA3047451A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型
CN110799180A (zh) 2017-06-26 2020-02-14 罗曼治疗系统股份公司 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
CN109091667B (zh) * 2018-09-18 2020-05-05 广东天普生化医药股份有限公司 人尿激肽原酶在制备治疗偏头痛药物中的用途及其组合物
CN116549619A (zh) * 2022-01-28 2023-08-08 江苏众红生物工程创药研究院有限公司 激肽原酶及其衍生物在治疗vci、psci或csvd中的应用
CN116549599A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 激肽及其衍生物在治疗vci、psci或csvd中的应用
CN116554267A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 聚乙二醇修饰的激肽或其变体和药物应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ582930A (en) * 2007-07-20 2012-11-30 Diamedica Inc Tissue kallikrein for the treatment of diseases associated with amyloid protein
WO2010009557A1 (en) * 2008-07-25 2010-01-28 Sanomune Inc. Tissue kallikrein for the treatment of parkinson's disease

Similar Documents

Publication Publication Date Title
JP2012524112A5 (enExample)
ES2762250T3 (es) Tratamiento combinado del cáncer
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
MX2011008616A (es) Peptidos utiles en el tratamiento y/o cuidado de la piel , mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
KR101891505B1 (ko) 혈구 감소를 예방 또는 치료하기 위한 약물의 제조에 있어서의 안히드로이카리틴의 용도
BR112014016085A8 (pt) composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
UY32599A (es) Formulación oral sólida de abt-263
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
MX337830B (es) Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas.
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
UA92453C2 (ru) Производные карбостирила и стабилизаторы настроения для лечения расстройств настроения
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2014515408A5 (enExample)
UA110463C2 (ru) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я
JP2011513437A5 (enExample)
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
US9220713B2 (en) Compositions and methods for the treatment of drug-induced hand-foot syndrome
JP2014506231A5 (enExample)
JP2018528259A5 (enExample)
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
ES3036485T3 (en) Combination comprising everolimus and amcenestrant